Biogen’s (BIIB) Overweight Rating Reiterated at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $292.00 target price on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Biogen from a […]
More Stories
McKesson (NYSE:MCK) Issues FY 2025 Earnings Guidance
McKesson (NYSE:MCK – Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share...
M. Kraus & Co Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)
M. Kraus & Co cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 0.2%...
Financial Survey: Gold Royalty (NYSE:GROY) & American International Ventures (OTCMKTS:AIVN)
Gold Royalty (NYSE:GROY – Get Free Report) and American International Ventures (OTCMKTS:AIVN – Get Free Report) are both small-cap basic...
iShares Bitcoin Trust (NASDAQ:IBIT) Shares Up 3.1% – What’s Next?
iShares Bitcoin Trust (NASDAQ:IBIT – Get Free Report)’s share price rose 3.1% during trading on Wednesday . The company traded...
Red Cat (NASDAQ:RCAT) Stock Price Up 17.1% – Still a Buy?
Red Cat Holdings, Inc. (NASDAQ:RCAT – Get Free Report) shares were up 17.1% on Wednesday . The company traded as...
Silvia Mccoll Wealth Management LLC Raises Stock Position in Vanguard Small-Cap Value ETF (NYSEARCA:VBR)
Silvia Mccoll Wealth Management LLC grew its stake in Vanguard Small-Cap Value ETF (NYSEARCA:VBR – Free Report) by 1.3% in...